Evidence map›Paper›PMID 40239632›Full record

ArticleCell reports. Medicine2025

Catalytic neural stem cell exosomes for multi-stage targeting and synergistical therapy of retinal ischemia-reperfusion injury.

Weiqiang Yang, Xiaojun Wang, Diwei Zheng, Jing Feng, Wenjun Kong, Yue Li, Guanghui Ma, Wei Wei, Yong Tao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weiqiang YangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China; Joint laboratory of Drug Delivery & Innovative Therapy built by Beijing Chaoyang Hospital & State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Xiaojun WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China; Joint laboratory of Drug Delivery & Innovative Therapy built by Beijing Chaoyang Hospital & State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China. Electronic address: wangxiaojun@mail.ccmu.edu.cn.
Diwei ZhengState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Jing FengDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China; Joint laboratory of Drug Delivery & Innovative Therapy built by Beijing Chaoyang Hospital & State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Wenjun KongDepartment of Ophthalmology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.
Yue LiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Guanghui MaState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; Joint laboratory of Drug Delivery & Innovative Therapy built by Beijing Chaoyang Hospital & State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, P.R. China. Electronic address: ghma@ipe.ac.cn.
Wei WeiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; Joint laboratory of Drug Delivery & Innovative Therapy built by Beijing Chaoyang Hospital & State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, P.R. China. Electronic address: weiwei@ipe.ac.cn.
Yong TaoDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China; Joint laboratory of Drug Delivery & Innovative Therapy built by Beijing Chaoyang Hospital & State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; National Engineering Research Center for Ophthalmology, Beijing, P.R. China; Engineering Research Center of Ophthalmic Equipment and Materials, Ministry of Education, Beijjing, P.R. China. Electronic address: taoyong@mail.ccmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuronal damage of the retina is a leading cause of visual impairment in patients with retinal ischemia-reperfusion injury (RIRI). Building on our clinical and experimental findings, the substantial decrease in catalase activity correlates with increased hydrogen peroxide (H

Indexed as

ExosomesNeural Stem CellsReperfusion InjuryRetinaRetinal DiseasesAnimalsAntioxidantsCatalaseDisease Models, AnimalHumansHydrogen PeroxideMaleMiceMice, Inbred C57BLNeuroprotective AgentsOxidative StressAntioxidantsCatalaseHydrogen PeroxideNeuroprotective Agentscatalytic antioxidantsexosomesretinal ischemia-reperfusion injurysynergistical therapy

Identifiers

PMID40239632
PMCPMC12047469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.